Small Cell Lung Cancer Limited Stage Clinical Trial
Official title:
An Exploratory Clinical Study to Investigate Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer
The purpose of this study is to evaluate the tolerability and toxicity of different dose of anlotinib combination with concurrent chemoradiotherapy in the treatment of limited-stage SCLC patients.
Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit and MET. The purpose of this study is to determine the maximum tolerated dose of anlotinib when combination with concurrent chemoradiotherapy. From low dose group up to high dose group, each one had 3 patients at least. Primary group received anlotinib 8mg. The dose of anlotinib would increase gradually until MTD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04543890 -
A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC
|
Phase 2 | |
| Completed |
NCT03059667 -
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01797159 -
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT03214003 -
Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC
|
N/A | |
| Recruiting |
NCT04418648 -
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
|
Phase 2 | |
| Recruiting |
NCT05651802 -
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
|
N/A | |
| Not yet recruiting |
NCT04189094 -
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
|
Phase 2 | |
| Recruiting |
NCT05945745 -
Molecular Analysis and Treatment Options of SCLC
|
||
| Recruiting |
NCT04602533 -
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
|
Phase 2 |